Wall Street Zen Upgrades Lumexa Imaging (NASDAQ:LMRI) to "Buy"

Key Points

• Wall Street Zen upgraded Lumexa Imaging from “hold” to “buy,” contributing to an overall analyst consensus of “Buy” and a $16.00 price target.
• Analyst targets range from $13 to $18, while ratings include two Strong Buys, two Buys and one Sell, reflecting generally positive but mixed sentiment.
• Lumexa reported quarterly EPS of $0.20, exceeding the $0.03 consensus estimate, on revenue of $264.16 million, and issued fiscal 2026 EPS guidance of $0.71–$0.77.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Saturday, Wall Street Zen reports.

Other analysts also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft set a $16.00 price target on shares of Lumexa Imaging in a report on Thursday, August 13th. Raymond James Financial set a $17.00 price objective on shares of Lumexa Imaging in a research note on Monday. Weiss Ratings restated a "sell (d)" rating on shares of Lumexa Imaging in a research report on Tuesday, September 22nd. KeyCorp initiated coverage on Lumexa Imaging in a research note on Thursday, September 24th. They set an "overweight" rating and a $18.00 target price for the company. Finally, Barclays lifted their price target on Lumexa Imaging from $9.00 to $13.00 and gave the company an "overweight" rating in a research note on Friday, August 28th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Lumexa Imaging presently has an average rating of "Buy" and a consensus price target of $16.00.

Lumexa Imaging Price Performance

Shares of NASDAQ LMRI opened at $10.32 on Friday. The business has a fifty day moving average price of $11.30 and a two-hundred day moving average price of $10.30. The stock has a market capitalization of $991.44 million and a PE ratio of -21.06. The company has a debt-to-equity ratio of 1.40, a current ratio of 1.44 and a quick ratio of 1.44. Lumexa Imaging has a fifty-two week low of $6.45 and a fifty-two week high of $19.45.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.17. The company had revenue of $264.16 million during the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. As a group, equities analysts predict that Lumexa Imaging will post 0.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lumexa Imaging

Several institutional investors and hedge funds have recently added to or reduced their stakes in LMRI. Squarepoint Ops LLC increased its holdings in Lumexa Imaging by 506.9% in the second quarter. Squarepoint Ops LLC now owns 79,934 shares of the company's stock valued at $902,000 after purchasing an additional 66,763 shares during the period. Readystate Asset Management LP lifted its holdings in Lumexa Imaging by 11.5% during the 2nd quarter. Readystate Asset Management LP now owns 250,533 shares of the company's stock worth $2,826,000 after buying an additional 25,778 shares during the period. AXQ Capital LP acquired a new position in Lumexa Imaging during the 2nd quarter worth about $128,000. Bank of America Corp DE bought a new stake in shares of Lumexa Imaging in the 2nd quarter valued at about $200,000. Finally, Jupiter Topco LLC acquired a new stake in shares of Lumexa Imaging in the second quarter valued at about $24,269,000.

About Lumexa Imaging

Lumexa Imaging, Inc NASDAQ: LMRI is a U.S. healthcare services company focused on outpatient diagnostic imaging. The company operates and supports imaging centers that provide noninvasive services used to detect, diagnose and monitor medical conditions.

Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and other diagnostic imaging procedures. Lumexa also works with radiologists and referring healthcare providers to deliver image interpretation and related clinical services.

The company's operations are primarily located in the United States, serving patients through a network of outpatient imaging facilities and affiliated radiology practices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.